Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Gwyneth Paltrow is considered a pillar of health in the wellness community, which has made her the subject of scorn in the past. Critics have deemed her “unrelatable” and her goals ...

Recent media coverage in the Nine newspapers highlights a surge in non-medical ultrasound providers offering "reassurance ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...

Endometriosis is a chronic and systemic inflammatory disease where uterine endometrial-like tissue grows outside the uterus. The most common symptom is debilitating pelvic pain before and during ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The expanded collaboration now allows Reddit to use Google’s Vertex AI, which enables users to build, deploy, and scale machine learning models and AI applications, the author notes. Easily ...